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are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor
clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians
do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data
from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology
patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology
(SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group,
patient advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium
(ABTC), and other partners are working together with the intent to double clinical trial accrual over the
next five years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology
and offer possible solutions.
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Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not 
easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical 
trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a 
poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from 
the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients 
asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) 
in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient 
advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium (ABTC), 
and other partners are working together with the intent to double clinical trial accrual over the next five 
years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer 





The prognosis for adult patients with malignant brain tumors remains poor with only minor improvements 
in survival over the past few decades. While many factors contribute to this lack of progress, a major 
impediment to improving outcomes is poor clinical trial accrual. In general, when cancer patients are 
eligible and offered a clinical trial, more than 50% of patients enroll.1-5 Yet, the percentage of patients 
who actually enroll on clinical trials is much lower. In 2002, Chang et al. reported that only 21.3% of 
malignant glioma patients participated in a clinical trial.6 Unfortunately, accrual to neuro-oncology trials 
has remained stagnant over the past decade. A 2016 survey of brain tumor patients by the National Brain 
Tumor Society (NBTS) revealed that only 21% of patients participated in a clinical trial and only 24% of 
patients were informed of clinical trials at the time of diagnosis.7 Similarly, a 2018 paper on the clinical 
trials landscape for glioblastoma (GBM) estimated that only 8-11% of newly diagnosed GBM patients 
enroll in clinical trials.8 Based on this information, the Society for Neuro-Oncology (SNO), NBTS, and 
the Neuro-Oncology Branch of the National Cancer Institute (NCI) partnered on a survey of over 350 
neuro-oncology providers in an effort to identify challenges and barriers to clinical trial referral and 
participation. According to results from this survey (described in the companion paper by Rogers and 
colleagues), less than 30% of all patients are referred for clinical trials, but over one-third of participants 
noted that their institution did not track clinical trial referral, making accurate estimates difficult (Rogers 
et al. submitted for publication).   
 
SNO, in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, 
patient advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium 
(ABTC), and other partners are working together with the intent to double clinical trial accrual over the 
next five years. There have been previous efforts to identify barriers to clinical trial accrual in cancer.9-12 
Here, we discuss the factors contributing to poor trial accrual specifically to neuro-oncology trials and 
offer possible solutions. We will focus on patient and community factors, disparities, physician and 






A. PATIENT AND COMMUNITY FACTORS  
Patient and community factors impeding clinical trial participation of brain tumor patients are poorly 
understood. Indeed, disease-specific research regarding these factors is critically important due to the 
influence of the illness on cognitive function, behavior, and motor skills, which can impair patients’ 
medical decision making, employment, and sense of control. This section evaluates patient and 
community factors that might impede trial participation with the goal of identifying opportunities for 
developing interventions to improve participation.  
 
Patient specific factors 
A wide range of brain tumor patient factors could influence clinical trial participation. Some of the factors 
which negatively affect participation in brain tumor trials, such as social disparities13,14, language or 
cultural barriers, and older age6, are common across oncology. Some factors are unique to the population 
given the impact of the disease on neurocognitive function.  
 
The timing and way in which clinical trials are discussed with patients may impact accrual, particularly 
depending on the patient’s level of understanding and the health care provider’s ability to communicate 
trial information. Lower educational achievement is a known barrier to clinical trial enrollment; previous 
studies have identified associations between education and patients’ ability to make decisions about 
clinical trial participation in other cancer types.1,15-18 Regardless of their educational background, the 
explanation of complex trial-related procedures by providers and lengthy consent forms may overwhelm 
patients and caregivers with no prior knowledge of clinical research methodology or terminology. The 
nature of clinical research and procedures such as randomization, blinding, and biospecimen collection—




add complications that may be perceived as unwanted interventions beyond routine care. Additionally, 
clinical trials are typically presented during the emotional and psychosocial upheaval of a new or 
recurrent cancer diagnosis.  
 
In prior studies, the quality of communication, a strong patient-physician relationship fostering a sense of 
trust, and a patient-friendly presentation of clinical trial information were factors associated with 
improved oncology trial participation4, highlighting the importance of communication and providing 
appropriate patient education. Verbal, written, video, and online review materials, carefully prepared in 
layman’s terms, as well as adequate time to address questions and concerns can prove invaluable to 
patients/caregivers pondering varied and complex treatment options. Sensitive attention to trial 
complexities, such as use of a placebo or blinded trial design, as well as availability of financial or other 
supportive resources (such as travel compensation, discounted lodging, etc.) can also help encourage trial 
participation.  
 
Some neurologic symptoms associated with a brain tumor may be negative predictors of trial enrollment. 
Based on neurocognitive testing and standardized research consent capacity measures, patients with 
malignant gliomas perform significantly below healthy controls with respect to appreciation, reasoning, 
and understanding of consents.19 Not surprisingly, patients with a greater degree of cognitive impairment 
are less likely to enroll onto clinical trials.20 Higher symptom burden may be associated with a lower 
performance score such as Karnofsky Performance Status (KPS), precluding enrollment on a trial due to 
traditional inclusion criteria requiring good performance status. Physicians may also be unwilling to 
expose patients with a borderline KPS to the burden of a clinical trial. Additionally, patients with 
cognitive impairment or a greater neurologic symptom burden may feel less independent; loss of 
autonomy itself has been inversely correlated with participation in clinical trials in other cancers.21 
Receptive or global aphasia raise concerns about a patient’s ability to provide informed consent and to 




tumor patients, additional studies are warranted to investigate the influence of cognitive function and 
symptom burden on trial enrollment and determine strategies to mitigate this barrier. Of course, some 
patients may not be suitable for trials, but there should be a relatively low threshold to consider trials for 
brain tumor patients given the poor results with standard therapies.  
 
Limited awareness of clinical trials 
Another important patient-related barrier to clinical trial enrollment is limited awareness of clinical trials 
and limited understanding of the overall goals of clinical research. Based on a survey of cancer patients 
and caregivers, most reported that their physicians did not discuss clinical trials as a treatment option and 
most believed that their physicians would have recommended clinical trials if trials were appropriate.22 
Indeed, in the 2016 NBTS survey of brain tumor patients, only 42% of patients were informed about 
clinical trials at any time during the course of their illness by their medical team.7 Although many centers 
do not have trials to offer patients, the crucial importance of clinical research in improving care for brain 
cancer is a message worthy of discussion with all patients regardless of stage of treatment (thus also 
helping dispel the myth that clinical trials are only for those with advanced disease). Unfortunately, 
increased awareness itself may not be adequate to expand patient enrollment in clinical trials.7 The most 
common incentive for clinical trial participation cited in the NBTS survey was to not only help “me” but 
also to help future brain tumor patients.7 This altruistic motivation is common in cancer patient trial 
participants, particularly in phase III clinical trials.23 A better understanding of the critical role of clinical 
research in advancing patient outcomes—in addition to the overall value of clinical research to society—
deserves greater public dissemination.  
 
Misconceptions about research study involvement 
Another barrier to clinical trial participation is the misconception about risks and benefits of research 
study involvement. For example, patient randomization to the control arm of a study might be perceived 




found that low trial enrollment might be related to a lack of understanding of details and availability of 
clinical trials by physicians in addition to their lack of familiarity with the principal investigators and sites 
where trials are available.24 A patient may feel that a physician is offering a clinical trial for his or her 
own selfish reasons rather than to provide the best care for the patient; this may lead to a perceived lack of 
personal benefit by the patient and limit engagement in clinical trials. Importantly, the design of a clinical 
trial can dissuade some patients from enrolling. All efforts to enhance trial enrollment will be enabled by 
greater involvement of patients and advocacy groups via their input into the design of clinical trials at an 
early stage of a trial’s development. One uncommon barrier (<10% of respondents) identified by the 
NBTS survey is the fear of experimental therapy toxicity, including life-threatening events.7 Clear, honest 
communication of realistic risks and benefits of therapeutic interventions may reduce these barriers and 
enhance brain tumor clinical trial enrollment.  
 
Patient-related logistical and cost constraints 
Another prominent barrier to trial enrollment is the distance required to travel to participate and the cost 
of participation.20,25,26 Travel can be a barrier for many reasons, including a patient’s inability to drive due 
to seizures, financial burden linked to travel and lodging expenses, time away from work for patients and 
caregivers, childcare costs, and overall stress related to travel. Opening trials at more centers, allowing 
delivery of radiation therapy or other standard of care (SOC) treatments closer to home, greater 
involvement of local oncologists, use of novel technologies such as telemedicine27,28, collection of 
patient-reported data through mobile devices such as the MyStudies app from the US Food and Drug 
Administration (FDA)29, trial-design changes such as reducing the number of clinical trial visits, and 
resources to facilitate travel and reduce lost income may all be factors which enhance trial participation. 
The FDA recently updated its guidance to clinical investigators allowing reimbursements to patients in 
clinical trials for lodging and travel.30,31 When feasible, investigators should consider budgeting such 





Education campaigns, brain tumor registries, and social media may reduce barriers to trial 
participation 
Education campaigns should focus on reducing barriers to trial participation. In addition, research is 
needed to identify the greatest barriers specific to brain tumor patients. The focus should be on the impact 
of neurologic deficits, symptom burden, cognitive dysfunction, and feelings of loss of control in addition 
to known general factors such as dispelling myths associated with clinical research (e.g., clinical trials are 
only a last-resort treatment). Development of a brain tumor registry to quickly identify newly diagnosed 
cases with specific molecular profiles across the country could enable targeted education for these 
patients and physicians for early intervention, highlighting the potential benefits of precision medicine 
trials. Similar efforts are in place using the Screening Patients for Efficient Clinical Trial Access 
(SPECTA) platform by the European Organization For Research and Treatment of Cancer (EORTC)32 
(NCT02307604). 
 
Social media can also help disseminate credible information about clinical trials to a broader audience 
(including rural communities, younger patients, patients with rare tumors, and underrepresented 
minorities), improve patient understanding about research, and provide a platform for communication 
between researchers, clinicians, patients, caregivers, and patient advocates.33,34 Approximately 70% of 
online adults in the United States are regularly on social media, and usage only continues to increase.35 
Social media may help engage patients in clinical research, particularly those from underserved 
populations. In an examination of recruitment strategies for studies of young adult female cancer 
survivors, internet-based recruitment resulted in the highest number and yield of participants.36 Because 
social media is inherently different from traditional print media including privacy concerns in this less-
controlled environment, the US National Institutes of Health (NIH) provide guidance to investigators on 





The internet, particularly Clinicaltrials.gov, is a frequent resource for patients and caregivers seeking 
treatment options but searches for clinical trials can be cumbersome and overwhelming. Efforts to 
simplify identification of local studies could include development of easily accessible clinical trial 
matching tools available through a website or a smart phone App, increased use of clinical trial 
navigators, and engagement with advocacy groups and provision of patient navigators to help find clinical 




The 2002 Institute of Medicine report entitled “Unequal Treatment: Confronting Racial and Ethnic 
Disparities in Health Care” first defined the concept of health care disparity as racial or ethnic differences 
in the quality of health care that are not due to access-related factors or clinical needs, preferences, and 
appropriateness of intervention.40 Disparities with respect to prevention, early intervention, and survival 
have been documented in multiple diseases, including cancers41-45 and in clinical trial enrollment for 
cancer46-48. There is also evidence that patients from subsets of ethnic minority groups may not be 
afforded the same opportunity to participate in clinical trials and thus benefit from advanced therapies 
offered via clinical trials.49-51 Additionally, given the advent and emphasis on advanced genomics and 
personalized medicine, biomarkers from diverse populations are less likely captured, thus limiting our 
ability to determine if true differences exist in mutational profiles across various ethnic groups.45   
 
While the incidence of primary brain tumors is higher in non-Hispanic White patients, there is conflicting 
evidence regarding survival outcomes as it relates to race.52-54 However, as in other cancers, clinical trial 
enrollment among minority populations remains poor. In this section, we will discuss challenges in 
accrual to clinical trials for under-represented ethnic minorities (URM), as well as possible approaches to 




people from the following groups: Black/African-American, Hispanic/Latino, Native American, Pacific 
Islander, and mainland Puerto-Ricans.55 It is important to note that disparities to care also exist for 
populations based on age, gender, socioeconomic status, and sexual orientation and the impact of these on 
care of neuro-oncology patients warrants further investigation. 
 
Access and referral patterns 
Patient-specific factors underlying limitations to accessing proper health care for URMs include lack of 
insurance or underinsurance, transportation issues, cultural and language barriers, and opportunity cost 
from income lost from work and other practical obstacles.46,47 Lack of insurance or underinsurance can 
directly impact access to clinical trials, especially if care at larger academic institutions with more trial 
options such as NCI designated Cancer Centers is not covered.47 Perhaps as an extension of insurance 
status, access to institutions dedicated to cancer care and clinical trials may also be dependent on referral 
patterns for care, which in turn may be contingent upon geography, the patient’s medical condition and 
preference, the preferences of the referring medical team and their awareness of trials, among other 
factors. Treatment planning may be interrupted and delayed especially in instances where initial surgery 
or biopsy is obtained at an institution separate from that of the specialist care providers.56 For patients 
from URM groups with wariness or unfamiliarity of the health care system as well as those with limited 
English or medical literacy, clinical trials may only be briefly discussed or deferred due to time 
considerations.47 While patient resources such as patient navigators and advocacy groups such as the 
American Brain Tumor Association (ABTA), the Brain Tumor Network (BTN), and NBTS are in place to 
guide patients and families through their treatment process, greater attention and support is needed for the 
most vulnerable patients or for those who may not have an awareness of the existence of these programs. 
 
To address larger issues such as insurance coverage and other socioeconomic determinants of health (e.g., 
income, education, habitat), a multidisciplinary effort by stakeholders including physicians, hospital 




current paper. A solution to this challenge in the immediate term would be to first establish a standardized 
management algorithm with proposed timing and steps in care for management of patients with brain 
tumors (Figure 2). Ideally, each step of the algorithm functions as a trigger or reflex, such that this may 
eliminate any uncertainty or hesitation in moving the patient through treatment in a smooth and 
uninterrupted manner. The algorithm would provide a framework for treatment planning within and 
across institutions ranging from large academic centers to smaller community settings and allow patients 
to better understand the necessary steps in their treatment course.  
 
Drawing on work which already exists through internal institutional and patient advocacy group patient 
navigator programs, dedicated patient navigator programs specific to clinical trials participation can be 
expanded, perhaps through patient advocacy programs, for vulnerable patients with limited literacy of 
health care systems or those most at risk to being lost to follow-up. As noted earlier, a specific patient’s 
care may cross various institutions; however, at the time of an initial diagnosis, they should be provided 
by the initial treating care provider with an overall framework of the treatment course, including options 
for treatment, the various roles of their treatment team, and opportunities for psychosocial support.  
 
Bias and mistrust  
The history of medicine is notable for transgressions with respect to race and ethnicity, which has laid 
groundwork for mistrust among URMs towards larger institutions including health care systems.40 In 
medical and research education, keen attention is paid to training and re-training to avoid errors in 
designing and carrying out treatment protocols. In a routine clinical encounter, however, unconscious (or 
implicit) bias has been determined to be a source of discrimination which may impact the treatment 
relationship. Communication may be poorer in what have been identified as “racially discordant 
interactions” between a racial minority patient and a non-racial minority physician.57-59 The medical care 
provider displays uncertainty as a result of misbeliefs about the patient (or their identity), and the patient 




instructions and the physician less likely to recommend a course of action or clinical trial, based on an 
assumption that the patient may not choose to participate.40,57 Although the impact of unconscious bias 
may be more challenging to quantify as it relates to overall survival outcome, this still represents an 
important key to establishing a treatment relationship between patient and physician. 
 
Whether through larger SNO/RANO led efforts or at a local/institutional level, there should be a 
commitment to ensuring that all members of a treatment team (physician, nurse, patient navigators) are 
trained in unconscious bias and receive updated training at intervals. Similar to medical school programs 
of cultural compentency60, institutions should establish metrics for success of the program and continually 
evaluate for efficacy and relevance.  
 
Lack of exposure to diverse workforce 
In the US, Black/African-Americans are 13% of the US population and Hispanic-Americans are 18% of 
the population, yet 2.8% of US oncologists identify as African-American and 5.8% as Hispanic.61 The 
weakening of this training pipeline is likely due to concerns around education, income, and opportunity. 
However, it is also compounded by a decline in URM physicians and medical students, owing to 
reduction in medical school recruitment and pipeline programs; limited exposure to oncology and 
oncology subspecialties in medical school, insufficient URM role models, and implicit bias in candidate 
selection.57,61,62  
 
Through an American Society of Clinical Oncology (ASCO) led taskforce established to increase racial 
and ethnic diversity in the oncology workforce, a strategic plan was developed to this end. As the 
functional and daily challenges faced by primary brain tumor patients are unique, SNO and partnering 
organizations should consider a parallel or separate pipeline program, aimed at recruitment of physicians 
from URM groups into neuro-oncology. URM student organizations such as the Student National 




clinicians, researchers, and leaders in neuro-oncology. Similar efforts can be made with respect to 
resident trainees. Efforts for pairing current medical students and resident trainees with faculty mentors or 
representation of SNO at national conferences may be a small step in establishing a longitudinal pipeline 
critical to ensuring equal, high-quality care for our patients. 
 
 
C. PHYSICIAN AND PROVIDER FACTORS 
Physicians and clinical providers play a key role in the clinical trial process. This includes the 
identification of patients for appropriate trials, discussion regarding the option of participation, 
assessment of patients on study, and compliance with trial conduct. In general, there are two main options 
for physicians to enroll patients into clinical trials: enrolling onto trials that are open at the physician’s 
own institution and referring patients for open trials at other institutions. The latter option is particularly 
important when good SOC options do not exist, when there are no available or appropriate trials at the 
physician’s own institution, and when patients are motivated to participate in a clinical trial at another 
institution. In this section, we focus on the interaction between the patient and their treating physician. 
Rogers and colleagues report that the most frequent barriers clinicians face include factors related to trial 
location (e.g., difficulty finding trials in the patient’s geographic area, patient being unable to stay for 
treatment at the academic site), lack of available slots on an existing trial, patient not meeting eligibility 
criteria, and limited staff resources (Rogers et al. submitted for publication). The importance of the 
physician’s role in trial accrual is strongly supported by the variance in accrual between physicians within 
a practice.63 The difference between “high” accruers and “low” accruers is unlikely due to different 
patient populations within the same practice and likely due to individual physician related factors. Here 
we identify and provide solutions to the common challenges that physicians and providers experience 






The option of participation in a clinical trial is a major part of professional practice guidelines such as 
those from the National Comprehensive Cancer Network (NCCN)64. As a scientific community, the 
review and discussion about local and regional clinical trial options should become part of the standard 
workflow for good clinical practice. If this discussion is missed, patients may not have the opportunity to 
participate in a trial that may be of interest to them.65 There are several potential barriers that limit this 
discussion. From a practical perspective, the provider may feel that there is insufficient time in an 
appointment to discuss clinical trials in addition to the standard therapies.66 Another challenge is the lack 
of knowledge regarding the potential trials that patients may be eligible for either at the provider’s own 
institution or at another site.18 This may be due to lack of time to search and identify potential studies for 
the individual patient. In fact, the burden of the clinical trial process has been identified as a major barrier 
for referring patients for clinical trials.67 However, most patients are unaware of available clinical trials 
and therefore the role of the physician in identifying clinically appropriate studies is critical.68 In addition, 
provider attitudes towards clinical trials are an essential factor for successful trial enrollment. Physicians 
who are motivated to present the trial in detail to patients, explain the relevance of the study intervention 
in their medical management, and encourage them to participate, are more likely to enroll. This is also 
perceived by patients who view their physicians as the most trusted health care professional source of 
health information.69 Another barrier is the unwillingness to refer patients to an outside institution where a 
trial is identified. When the referral does not happen, it is a missed opportunity to both enhance patient 
care through clinical trial participation and to collaborate with referral centers.  
 
There are other challenges to clinical trial enrollment. Some physicians may not want to enroll patients in 
randomized studies if they feel uncomfortable with the presence of a control arm, as discussed further in 
the clinical trial factors section. In addition, the physician’s perception about risk of toxicity in an 
individual patient with factors such as older age, worse KPS, extensive comorbidities, and a high level of 
symptom burden may negatively influence a physician’s decision to recommend a clinical trial. Age is a 




trial participation in glioma patients6. The interaction between age and risk of toxicity perceived by the 
physician has been shown to influence enrollment of elderly women in breast cancer clinical trials.71 
Given the importance of clinical research in improving outcomes, it is critical to minimize physician bias 
and its influence on clinical trial participant selection.  
 
Some physicians may have the perception that the patient is not interested in participating and may be 
concerned about an adverse effect on the physician-patient relationship.72 Both of these challenges may be 
addressed by allocating time for specific discussions with patients. These discussions are actually similar 
to discussions that clinicians have with patients during standard treatments, where clinicians will discuss 
with patients about risks, benefits and candidacy for any standard therapy. Additional time is also spent in 
the care of patients enrolled on clinical trial, including additional documentation, assessment of adverse 
events, tumor measurements, and regulatory activities. Whether physicians should be compensated for the 
additional time required to address clinical trial questions (similar to the billing mechanism in the US that 
supports the additional time required for end of life discussions) is unclear; however, what is clear is that 
identifying and presenting clinical trials to patients does take time. Another factor that may also influence 
trial enrollment that is closely related to the physician-patient relationship is the potential conflict 
physicians perceive as their role as caregiver versus scientist.66 In addition, the physician may have an 
interest in enrolling patients on a particular study over another concurrently run trial, which can skew 
accrual and may or may not be the best fit for the patient. Potential solutions to these challenges are 
shown in Table 1. 
 
Physician-related logistical barriers 
The interest and enthusiasm for research participation by physicians may vary between specialties, and 
between clinical practice models, such as academic versus private practice versus hospital based. The 
physician financial compensation model may influence the likelihood of recruitment to trials available 




consideration. In the US, physician compensation is often tied to relative value units (RVU) production, a 
measure of value used in the reimbursement formula for physician services. As detailed above, trial 
accrual and participation increase the time and complexity of patient care that may reduce physician 
efficiency, with a subsequent reduction in RVU production. Therefore, many physicians regard research 
participation as a “volunteer” activity. If a patient is referred to another center for trial participation, the 
result is a loss of revenue for the referring physician and, often more importantly, his or her institution. 
Allocation of RVUs for research-related activities (research RVUs73,74) may be a strategy to incentivize 
greater participation, although requires a concerted effort between physicians, institutions, and payors to 
provide direct and indirect incentives for participation in research activities . Expanding authorship to 
more physicians who accrue to trials75 is another strategy, particularly if recognized by institutions for 
academic promotion.   
 
The clinical operations play an important role to support physicians in enrolling patients in clinical trials. 
For example, adequate staff effort is critical to secure timely referrals and to ensure safe continuity of care 
in cases where a trial is not available on site. Potential solutions to encourage trial accrual related to 
logistical concerns are shown in Table 1.   
    
Physician burnout 
Physician burnout related to clinical research is a complex problem.76 As outlined above, physicians can 
experience significant challenges regarding accrual of patients to clinical trials. These challenges can be 
frustrating and can harm the motivation of providers to enroll, or even to discuss clinical trials as an 
option with their patients. Potential solutions can include supporting research navigators who can alleviate 
the workload of curating and reviewing clinical trials for patients and addressing the financial constraints 
that physicians face.72 In looking into the future, new technologies may be able to assist in decreasing the 
physician’s burden, for example, artificial intelligence may help screen patients for eligibility to clinical 




affordability and the integration of such technologies will be key elements for their access and use. 
Electronic medical records, which are widely available today, makes clinical information easier to access 
and may assist in clinical research, particularly for trials that are available at the same institution.  
 
 
D. CLINICAL TRIAL FACTORS 
The development and implementation of clinical trials may adversely affect trial accrual and enrollment. 
Clinical trial factors that serve as barriers include the lack of input from patients, caregivers, and 
advocates in clinical trial design; lack of engagement with local health care providers in clinical trial 
implementation; overly stringent participant eligibility, and challenges associated with incorporation of 
novel technologies into neuro-oncology practice. Here, we discuss general principles across different 
types of clinical trials. There are additional factors affecting accrual depending on the type of clinical trial 
(i.e., early phase trials versus late phase trials, randomized versus single arm studies, sponsored versus 
consortium versus investigator-initiated studies) which are worth further evaluation.  
 
Trial factors affecting patient participation and health care provider engagement  
Incorporation of feedback from key stakeholders including patients, caregivers, and advocates early in the 
developmental process of a clinical trial can provide invaluable perspectives that may markedly enhance 
how user-friendly and attractive a trial is to patients. Often such input addresses practical and logistical 
issues not appreciated by investigators focused on the trial’s ability to address its key objectives. An 
important example, repeatedly raised by patients and caregivers, is that clinical trials should incorporate 
flexibility to allow study assessments that are considered SOC, particularly laboratory, imaging, and 
physical examination evaluations, to be performed locally whenever possible. Similarly, allowing 
standard therapies, such as radiation therapy or approved systemic therapies, to be administered locally 
according to established guidelines rather than at the trial center would ensure continuity of care, enhance 




heighten enthusiasm among local clinicians who value remaining a key contributor for their patients 
enrolled on a trial and lessen the financial disincentives of referring to another institution.  
 
On the other hand, evaluations and treatments are typically required to be performed at the study center, 
even those that are SOC because of perceived and actual regulatory requirements specifying that data be 
incorporated into a study database, and hence subject to audit, and be obtained from a validated, quality 
controlled, and certified source. For example, in the US, sponsors/investigators for studies under an 
Investigational New Drug (IND) agreement are compelled to add laboratories, imaging centers and local 
treatment providers to the FDA 1572 form with appropriate credential certifications filed in the 
participant’s study record. Rather than bother with this significant administrative effort and associated 
risks of potentially missed or inaccurate data, many sponsors/investigators simply opt to require patients 
to travel to the study center for all evaluations and treatments. Although such regulatory considerations 
are ultimately based on ensuring patient safety during trial participation, they can impose a significant 
burden on patients/caregivers by requiring an inordinate frequency of study center visits. Better 
clarification of study specific regulatory requirements between investigators, sponsors and auditors as 
well as a willingness to allow standard assessments and treatments to be performed locally by 
investigators for trials, despite the additional effort, will be important to lessen the impact of this issue on 
clinical trial accrual. In this way, visits to the study center are reserved for evaluations that are critically 
relevant to the investigational therapy.  
 
Eligibility criteria 
Excessively stringent eligibility criteria may also impede accrual. Although a growing number of trials 
appropriately restrict eligibility to a subset of patients with tumors exhibiting a specific mutation or 
biologic feature being targeted by an investigational agent, many other eligibility criteria are 
unnecessarily restrictive, excluding patients who could effectively contribute to addressing the study’s 




histopathologic grade IV glioblastomas, those at first or second recurrence, and those who have not 
progressed on prior bevacizumab, while in reality, patients with lower grade, isocitrate dehydrogenase 
(IDH) wildtype gliomas or even uncommon primary malignant CNS tumors (for whom clinical trials 
rarely exist), or those with unlimited number of recurrences or who have progressed on prior 
bevacizumab, could contribute to determine safety and a maximum tolerated dose ( MTD) / 
recommended phase 2 dose (RP2D). For these early trials where safety is the primary outcome and 
treatment is not specifically targeted at a specific histology, specified laboratory criteria and performance 
status should be considered the main eligibility criteria for participation. An exploratory cohort of specific 
histology or treatment history could be incorporated once the MTD/RP2D is defined. 
 
The definition of the most appropriate SOC for each and every patient is beyond the scope of this article, 
but concurrent use of tumor treating fields in combination with adjuvant temozolomide for newly 
diagnosed glioblastoma is a common exclusion criterion in many current trials. This may unnecessarily 
exclude some patients from trial participation. The decision to exclude concomitant use of tumor treating 
fields in trials for newly diagnosed glioblastoma should depend on whether there is a scientific reason to 
do so (i.e., potential interference with the therapy being evaluated, with the evaluation of side effects from 
therapy, or with the endpoints of the study). For randomized clinical trials, if tumor treating field use is to 
be allowed for patients on study, proper stratification should be utilized to control confounding effects. 
 
Some specific eligibility criteria can also be inappropriate for some phase II and III trials. For example, 
trials with a primary efficacy endpoint of progression-free (PFS) or overall survival (OS), should not 
exclude participants who have undergone a gross total resection prior to study enrollment including trials 
on recurrent glioma. Although patients without measurable disease cannot be included in the 






US regulatory bodies recognize the importance of loosening overly restrictive eligibility criteria when 
appropriate.78 Indeed, ASCO, Friends of Cancer Research (Friends), and the FDA examined specific 
eligibility criteria for population groups historically excluded from trials including patients with brain 
metastases and recommended ways to broaden eligibility criteria for these populations in cancer clinical 
trials. The RANO Brain Metastases Working Group have made similar recommendations.79 
Subsequently, the National Cancer Institute (NCI) pledged to utilize these broadened eligibility criteria in 
clinical trials going forward. A remaining barrier is the continued exclusion of glioma patients from most 
phase I trials in cancer based on outdated concerns80,81. An ongoing effort is needed to ensure that 
eventually gliomas patients will routinely be included in phase I trials if there is biologic rationale and the 
drug has reasonable access across the blood-brain barrier.  
 
Novel technology development 
Comparative studies 
In neuro-oncology as well as other cancer indications, trials assessing novel technology interventions pose 
further challenges for accrual associated with clinical equipoise. Do we have the clinical equipoise of 
“first do no harm” prior to embarking on randomized comparisons of technology? The example of proton 
versus photon radiation therapy underscores such a challenge. For this technical improvement 
comparison, the treating physician and the patient are both aware that one technology can reduce 
unwanted and unnecessary radiation dose to normal tissues. Patients and treating physicians may 
disregard such trials due to concern of randomizing to the “less desirable” arm. This lack of equipoise in 
technology testing serves as a major impediment to accrual and is underscored by several languishing 
proton versus photon therapy or intensity-modulated radiation therapy (IMRT) versus standard 
radiotherapy phase III trials (e.g., NCT021790860). In this context, third party coverage decisions, 






Conventional trials incorporate traditional endpoints such as progression-free survival (PFS), overall 
survival (OS), and response rate. In contrast, technology trials may be best suited to provide results 
focused on “unconventional endpoints”. For example, the fluorescent dyes used to enhance surgical 
resection of gliomas categorically demonstrate the ability to produce a more complete tumor resection, 
which translates to short-term, but not long-term survival benefit, and therefore, FDA approval of such 
agents lagged Europe’s approval by more than a decade. Endpoints for technology trials need to be 
tailored to the expected outcome to be tested. For example, craniospinal irradiation with protons might 
permit a greater ability to provide dose-intense chemotherapy for medulloblastoma patients, or volume-
sparing radiation techniques might cause less lymphopenia, or preoperative stereotactic radiosurgery 
(SRS) might reduce the local failure rate and pattern observed with post-operative SRS of brain 
metastases. Consideration of unconventional endpoints may be appropriate beyond technology trials such 
as the use of seizure control, change in neurocognition, or preservation of neurologic function as 
endpoints for lower-grade glioma trials.83 However, these endpoints are “non-traditional”, and therefore 
often not considered germane, leading to incorporation of traditional yet less appropriate endpoints that 
may impact enthusiasm for accrual. 
 
 
E.  SITE AND ORGANIZATIONAL FACTORS 
Clinical research is distinct from routine clinical care. Centers with clinical research capabilities have 
specialized personnel, training, infrastructure, resources, dedicated research nurses, specialized 
institutional facilities for specimen collection and analysis, infusion centers, and imaging. Clinical trials 
for brain tumor patients have become increasingly complicated in recent years, having evolved into more 
subgroup-focused studies, and therefore enroll smaller numbers of patients per trial. Genomic profiling, 
patient screening, and added procedures require greater infrastructure support. At many larger centers, 
additional sources of research support are used, such as philanthropy and funding from not-for-profit 




funding is highlighted by the fact that centers in the US with NCI- or industry-sponsored clinical trials 
have greater trial enrollment84,85, whereas unfunded sites have found a lack of specialized resources to be 
a barrier to trial enrollment86.   
 
It follows, therefore, that health care organizations are critical to the successful conduct of neuro-
oncology clinical trials. Even if physicians are engaged in research and eligible patients are available, 
accrual to clinical trials is dependent upon the proper stage being set by the organization. If health care 
organizations focus on setting the stage with infrastructure, clinical practice models, and appropriate staff 
necessary for clinical trial conduct, then trial accrual to neuro-oncology studies will improve. 
 
At present, many clinical centers do not view providing access of their patients to clinical trials as a goal 
of high or even modest priority. Internationally, this is also true for academic centers since their 
reimbursement systems usually do not differ from non-academic centers and since patients enrolled into 
clinical trials incur more administrative effort, but often less income. Thus, organizations are often faced 
with difficult decisions when funding different aspects of patient care. At a different level, publicity 
generated by the participation in clinical trials is usually limited and clinical centers tend to be sensitive to 
activities that raise national or local publicity. The major administrative and financial burdens may differ 
somewhat between countries and individual sites, but commonly include the institutional review boards 
(IRB) or ethics committees, challenges related to contracting between trial sponsors and the institutions, 
maintaining compliance with research billing, and financially supporting research support staff. 
 
Cancer care accreditation as an incentive for trial enrollment 
Accreditation is a useful tool to recognize sites for clinical excellence. In the US, the Commission on 
Cancer (CoC) recognizes cancer care programs for their commitment to provide comprehensive, high-
quality, and multidisciplinary patient centered care. Research participation is an integral component of the 




research participation, which supports the financial investment cancer centers put towards research 
activities. The development of accreditation for neuro-oncology centers through the Society for Neuro-
Oncology (SNO) would spur organizational and site investment in research infrastructure, similar to what 
is seen for the general oncology practice through CoC accreditation. 
 
IRB issues 
Centralizing operations may also relieve some of the administrative and financial burdens for individual 
sites. Moving towards a central IRB (e.g., on a country or trial level) could be an important step that 
remains yet to be realized in most countries; moreover, issues remain on an international level, notably 
with European involvement since processes of harmonization among different countries in Europe remain 
slow. However, even when a central IRB is available, not all institutions will recognize that approval in 
lieu of their own internal processes. In the US, a central IRB is now required for all multi-site, NIH-
funded studies, which has relieved a significant burden from individual sites and has led to more rapid 
trial conduct.   
 
Contracting issues 
Contracting challenges more often come from the institution than from external trial sponsors. Both 
industry and cooperative study groups prefer to institute a single contract per site which facilitates trial 
conduct and money flow, but this requires contract review, cooperation, and communication at the 
various levels within each institution. Supporting disciplines like pathology, radiology, radiation 
oncology and pharmacy often request separate contracts which drives administrative burden and cost. 
Contracting issues can be especially problematic for investigator-initiated multicenter trials and greater 
use of master contracts would reduce the timelines involved. 
 
Another and often under-recognized challenge relates to the determination of which study-related events 




that SOC procedures should be covered by traditional means (e.g., insurance or national health care plan) 
and that experimental procedures including additional imaging, blood tests, etc. should be covered by the 
sponsor. Often there is some disagreement as to which medical tests, measures, and tasks should be 
considered SOC and which should be considered trial-related. While some of these costs may be covered, 
at least in part, by the sponsors, there are certain costs (for example, the primary investigator’s 
professional time) that are not recognized. The level of necessary insurance coverage for clinical trial 
conduct may add complexity in some countries. In the US, these coverage determinations come in the 
form of a Medicare Coverage Analysis (MCA). It has been recognized that for each individual site to 
complete a separate MCA is unnecessary. The development of central MCAs which are provided for NCI 
cooperative group trials is ongoing.  
 
Another significant expense relates to the processing of adverse events (AE) reports. These reports are as 
important to the evaluation of a new treatment as are the primary outcome measures, and the amount of 
time spent on recognizing and reporting AEs is typically not covered in clinical trial contracts. These 
reports require the input of the investigators, research nurses, protocol managers, and other administrative 
personnel; and they often require multiple revisions in collaboration with the study sponsor. The most 
significant cost of these activities is time, particularly that of the primary investigator. The primary 
investigator is also expected to attend steering committee meetings (in person or by telephone) and other 
internal research regulatory meetings, which also deplete the finite resource of time and which are usually 
not reimbursed. Especially if an investigational agent is investigated in several parallel large trials, the 
number of serious adverse events reports may prevent adequate reading. 
 
Clinical practice models 
Organizational support of a clinical practice model that fosters research participation is also essential to 
improve neuro-oncology clinical trial accrual. Practice models may vary between academic and 




including phase I sections where cancer trials across tumor entities are conducted) as opposed to 
decentralized models where small dedicated teams take care of brain tumor patients, both outside and 
within clinical trials. The former units are commonly more sustainable, better capable of more complex 
trial supportive measures and often preferred by institutions whereas the latter are more likely to meet 
specific requirements addressing the specific needs of brain tumor patients, notably their impairment 
including aphasia, paresis, or seizures. Practice models in community centers vary widely, which relate to 
various factors including whether neuro-oncology patients are seen in a neurology clinic versus a general 
medical oncology practice, or whether they are seen in a rural or urban setting. In general, research 
subjects in community practices are not seen in a separate unit. Thus, any guidance towards developing 
criteria for a clinical practice supporting research activities must be broad to include multiple practice 
models. The value of a dedicated assessment tool to benchmark clinical trial infrastructure is currently 
being explored.87  
 
For several reasons, enrolling patients into clinical trials becomes even more difficult if the respective 
disease is diagnosed and treated in a multidisciplinary fashion. Tailoring diagnosis and treatment 
strategies to individual patients with brain tumors is commonly believed to be done best in a 
multidisciplinary tumor board which a priori requires additional resources from all departments involved. 
Tumor boards represent the ideal setting for research staff to gather feedback about upcoming trials and to 
educate all departments about open studies. Such boards also appear to be the best platform to assure that 
eligible patients for each open trial are readily identified. Still, since disease experts cannot be expected to 
universally agree with all trials of the institution’s portfolio, it is important that, once a decision to join a 
trial is made, the whole team of disciplines supports this trial, notwithstanding potential reservations of 
individual team members. This is particularly relevant for clinical trials which may be perceived to 
challenge one’s own discipline (e.g., trials which examine withholding surgery or radiotherapy). Also, 
requirements for time consuming molecular testing can imply that eligibility for a trial becomes 




bring their services to the trial without being involved and without formal recognition. To overcome this 
threat requires strong leadership of the multidisciplinary team and a broad institutional mindset that 
considers a strong clinical trial portfolio an asset to an academic medical unit. Tumor boards, with 
involvement of outside experts or use of virtual tumor boards, are particularly useful for community 
practices as this may represent the sole point in time where the full multi-disciplinary team is together.   
 
Physicians and research staff 
Specific challenges associated with physician engagement in clinical research were discussed previously 
in this article. Physician engagement with research varies within each clinical trial site, and thus accrual 
suffers if particular physicians are not engaged.63 This is particularly true in community settings as 
opposed to academic settings. Non-research-focused clinical centers, including community centers, may 
have fewer incentives to enroll patients in clinical trials. Physicians in larger academic centers are 
evaluated and incentivized with promotion, tenure, and academic credit for developing—and enrolling 
patients in—clinical trials. In the US, the same incentives are typically absent at smaller community 
hospitals and smaller academic centers, where success of the provider and center might be based on 
revenue-generating procedures and overall patient volume (e.g., RVU-based incentives). Usually, due to 
pressures to increase patient volume activity, protected time is limited for community physicians to open 
clinical trials and spend the time necessary to explain the value of clinical research to patients. A greater 
collaboration between research-based centers and community partners in local or state-wide networks as 
well as enhancing incentives for patient enrollment in clinical trials (discussed previously in section C: 
physician and provider factors) could greatly improve trial accrual and patient satisfaction.  
 
In the US, up to 80% of cancer patients are treated in community settings, highlighting the importance of 
greater partnership between academic centers and community physicians. Educational efforts focused on 
community physicians to emphasize the importance of clinical research would be helpful. Although 




tumor community identifies optimal strategies to increase clinical trial awareness. Closer academic-
community collaboration is essential. Realigning incentives within the community is important to 
facilitate patient referrals to centers of excellence for enrollment. Medicare, Medicaid, and third-party 
insurance reimbursements could be linked to patient trial enrollment. Additionally, opening more clinical 
trials in community centers may lead to greater patient participation.   
 
Nonetheless, each health care organization maintains the ultimate responsibility to hire physicians 
engaged in research activities and to maintain engagement by developing the infrastructure and clinical 
practice model necessary to facilitate physician involvement in research. If sites place an emphasis on 
research, they will seek to hire new physicians that share similar goals. To maintain engagement, sites 
may develop strategies to recognize and financially reward physicians for research activities, such as a 
research RVU system.  
 
In addition to physicians, research staff and support staff at an institution including nurse practitioners, 
nurses, study coordinators, social workers and translators play a critical role in trial accrual. These 
personnel are crucial in establishing patient trust in otherwise complex and impersonal medical systems 
and provide a more compassionate and human touch to necessary medical encounters and decision 
making. At many research institutions, especially community sites, the research nurse is the primary point 
of contact for patients to learn details about clinical trial participation. This interaction plays a key role in 
whether a patient elects to participate in a particular trial. Development of education materials and 
accreditation specific for neuro-oncology will improve each site’s ability to hire and maintain support 
staff necessary for the conduct of trials and to enhance accrual. 
 
 





More research is needed to better define the factors specific to neuro-oncology affecting accrual. To better 
understand this issue, clinical trial investigators should systemically document the reasons why patients 
do not enroll on trials. However, an analysis alone of the complex factors contributing to poor trial 
accrual to neuro-oncology trials is insufficient. The next step is to determine a roadmap to overcome these 
barriers (see Table 1 for summary). Borrowing from the field of behavioral economics, we must find 
“nudges”90 that can effect significant, long-lasting change and promote clinical trial participation. 
Provider and patient educational campaigns as well as engagement with advocacy groups may help 
change the mindset of physicians, patients, and caregivers to one where enrollment in clinical trials is the 
best option for most patients. This is now reflected in the NCCN guidelines for Central Nervous System 
Tumors where clinical trials are now the preferred option for most tumors.64 We must also harness 
modern technology to spread information about clinical trials through social media campaigns, smart 
phone Apps or internet-based clinical trial matching services that simplifies clinical trial searches for 
patients and caregivers, increasing the number of patient navigators to guide patients through the process, 
as well as creation of national brain tumor registries where patients can contribute tumor tissues for 
sequencing which may help pair them with clinical trial options. Until we can expand clinical trial 
opportunities to more community-based settings (perhaps through a more efficient national clinical trial 
network, allowance of SOC components of the trials to be performed locally, and use of telemedicine for 
virtual visits), any patient with a GBM or uncommon brain cancer should be offered a referral to a major 
neuro-oncology center(s) in their relative proximity for consideration of clinical trials.  
 
We must also critically evaluate clinical trial design that fosters accrual and removes excessive hindrances 
for participants. Continuing the momentum of work by ASCO/FOCR in collaboration with NCI, we will 
plan to work with the neuro-oncology community and clinical trial consortia to modernize eligibility 





However, these efforts to increase clinical trial accrual are likely to have limited impact if there are 
insufficient good quality trials. It will be critical that parallel efforts be undertaken in neuro-oncology to 
address this issue as well. How this can be accomplished is beyond the scope of this paper, although the 
neuro-oncology community must work together to increase the number of high quality clinical trials, 
especially in the NCI National Clinical Trials Network in the US and the EORTC in Europe, and to 
develop more trials utilizing efficient clinical trial designs (i.e., adaptively randomized trials such as 
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TABLE 1: Factors impacting accrual and potential solutions  
Challenges Potential solutions 
A: Patient and Community Factors 
Hindrances to patient’s decision-
making ability, including low level of 
education, limited understanding of 
clinical trials, and impact of disease on 
neurocognitive function 
• Provider education to improve communication with 
patients regarding clinical trials (including written and 
online materials and videos) 
• Engagement of patients and providers with advocacy 
groups 
• Use of clinical trial patient navigator 
Patient’s limited awareness of clinical 
trial opportunities  
• Patient education campaigns focused on reducing 
barriers to trial participation 
• Brain tumor registry to help providers identify trial 
eligible patients and to provide an opportunity for 
outreach to those patients 
• Simplify the ability to identify local and national trials 
through improved online search tools, smart phone apps, 
or clinical trial patient navigators 
• Engagement with patient advocacy groups, brain tumor 
support groups, and use of patient navigators 
Patient misconceptions about research 
study involvement including negative 
personal and family attitudes about 
clinical trials and perceived lack of 
personal benefit 
• Patient education campaigns focused on demystifying 
clinical trials and dispelling rumors about them 
• Engagement with patient advocacy groups which can 





Suboptimal (i.e. poorly timed or rushed) 
discussion of clinical trial opportunities 
with overwhelmed patients/caregivers 
• Heighten empathy for patients/caregivers 
• Incorporate multimedia materials to effectively describe 
in layman’s terms the study rationale, potential 
benefits/risks and logistics 
• Improve informed consent documents and processes to 
facilitate greater understanding of the issues involved in 
clinical trial participation  
• Provide enough time for patient/caregivers concerns to 
be addressed; incorporate additional research team input 
from nurses, mid-levels, and navigators 
• Refer patients to brain tumor patient advocacy 
organizations for additional support and access to 
patient navigators 
Concerns about the complexity and 
difficulty of complying with protocols, 
cost, and time/convenience  
• Design trials that are more patient friendly by obtaining 
their input 
• Resources to facilitate travel and reduce costs of trial 
participation such as parking, housing, and absence 
from work 
• Ensure coverage of routine patient care costs in clinical 
trials by both federal and private payers 
• Open larger number of trials at smaller centers (a role 
especially for the National Clinical Trials Network in 
the United States) 
• Use novel technologies such as telemedicine to 




• Trial-design changes aimed at reducing the number of 
clinical trial visits 
B: Disparities 
Access and referral patterns • Establish standard paradigm for referral of patients to 
neuro/medical oncology 
• Implementation of patient navigators dedicated to 
support of URM/vulnerable patients 
• Establish partnerships with community-based 
organizations serving URM 
Unconscious bias 
 
• Unconscious bias training with regular evaluation of its 
efficacy and relevance 
Lack of diversity in oncology 
workforce 
• Strengthen pipeline of URM candidates into neurology, 
oncology, neurosurgery, and radiation oncology 
C: Physician and Provider Factors 
Failure to discuss clinical trials as an 
option with patients 
Change standard practice to one where clinical trials are 
always discussed as an option in addition to existing 
standard therapies, particularly at two timepoints: 
• When formulating the initial plan of care. 
• At the time of disease progression or disease recurrence. 
• Early on, dispel potential patient and caregiver attitudes 
that clinical trials are only for a time when all other 
options have run out, especially since patients who are 
heavily pre-treated are less likely to qualify for trials 
Time and inconvenience • Trial navigators and/or electronic tools (e.g. apps) to 




• Brief trial summaries pitched at physicians and at 
patients to provide a high-level overview of the trial 
rationale, design, risks/benefits, and visit schedule can 
distill complex information into some of the key 
elements 
• Optimizing and streamlining referral processes on both 
the referring and receiving ends to reduce the barriers to 
referring patients to outside institutions for trials. 
Lack of knowledge • For complex cases scheduled in advance, care team 
members could prepare ahead of the encounter to gather 
information on the best course of action 
• If preparing ahead of the encounter is not possible, an 
alternative could be to acknowledge the complexity of 
the patient’s case, and explain that further discussion 
with colleagues will take place (i.e., multidisciplinary 
tumor board) to identify the best course of action 
Lack of information about available 
clinical trials including eligibility 
criteria 
• Take advantage of resources such as a clinical research 
navigator and on-line matching tools (e.g. apps), who 
can help identify clinical trials available at the 
institution that may be appropriate for each patient 
• When a patient is a good candidate for clinical trials and 
there is not a trial available at the provider’s institution, 





• Efforts to develop trial search engines which can 
provide accurate and appropriate potential trial matches 
while minimizing manual data input from the provider, 
and which can filter for key factors (geography, stage, 
disease status, lines of therapy, relevant biomarkers) are 
underway and should continue 
Lack of willingness to refer a patient to 
another center for study (including 
financial incentives) 
• Encourage a change in culture to always consider 
referring patients to centers with trials if one is not 
available locally, if practically feasible. 
• Allow patients to receive some of their evaluations and 
treatments with the referring physician to reduce the 
sense that the physician is “losing” their patients; to 
validate the importance of a continued connection 
between the referring physician and the patient; to 
reduce the financial disincentive to refer patients; and to 
support stronger collaborations between oncology teams 
at the referring and trial sites 
Lack of Incentive • Consider a research RVU system that compensates for 
clinical trial related activities  
• Increase possibility of authorship for physicians who 
enroll patients into clinical trials 
Concerns regarding a patient’s interest 
and ability to participate 
• A candid discussion with the patient and the research 
staff, ideally during the encounter to discuss treatment 
options, should be conducted to address any source of 




Concern about the interference in the 
physician-patient relationship 
• Discussions about goals of care, patient’s preferences 
and expectations should be done during the clinical trial 
in the same manner as they are done during routine 
clinical care 
Conflict between the physician’s role as 
caregiver versus scientist 
There are at least three strategies to help mitigate this 
concern: 
• To place the patient’s needs and preferences first 
• To enroll or refer to trials which are scientifically valid 
and designed in a clinically justifiable manner 
• To explain the differences between the role of the 
primary oncologist and the role of the clinical 
investigator, particularly when they are embodied in the 
same person 
• Ask patients for any source of concerns about conflicts 
between the roles, and address them 
Physician burnout • Understand and acknowledge the effect that clinical 
trials can have on physician burnout 
• Work with institutional leadership to emphasize the 
value of access to clinical trials and the need for 
resources to facilitate clinical research. 
• Work with the research staff, research nurses, clinical 
research coordinators and other personnel to address 
challenges to distribute the burden across the trial team.  
• Future platforms, such as artificial intelligence may 




•  Shared electronic medical records across institutions 
may improve access. 
D: Clinical Trial Factors 
Patient/caregiver hardships due to 
frequent study center visits limit 
enthusiasm for trial participation 
• Incorporate patient/caregiver/advocate feedback into 
early drafts of clinical trial during development  
• Allow study assessments and treatments, especially 
those considered “standard of care” to be done locally;  
• Require study center visits only when critically relevant 
to the study therapy; 
• Proactively incorporate patient/caregiver considerations 
into need for regulatory requirements for source 
documentation 
Inefficient clinical trial design features  • Incorporate multi-stage, multi-arm trials with adaptive 
randomization 
• Incorporate careful toxicity and efficacy stopping rules 
• Consider lower statistical power thresholds for non-
registration efficacy trials 
• Involve at an early stage of clinical trial design patient 
advocacy organizations, patients and caregivers  
Excessively stringent eligibility criteria 
limit trial participation 
• Limit inclusion/exclusion to criteria critically relevant to 
study primary endpoint 
• Ensure eligibility criteria do not preferentially exclude a 
demographic or racial group, e.g. upper or lower age 




associated with demographic or socioeconomic 
subgroup unless specific rationale for exclusion exists. 
• Include patients with primary and metastatic brain 
tumors in early phase oncology clinical trials 
Technology trials ignore clinical 
equipoise challenges and incorporate 
traditional trial endpoints 
• Allow non-traditional primary endpoint/s that addresses 
key clinically meaningful objective of technology being 
assessed 
E: Site and Organizational Factors 
Clinical research requires specialized 
personnel, training, infrastructure, 
resources 
• Effective leadership of a multidisciplinary team and 
organization culture to promote accrual  
• Adequate infrastructure to allow clinical research 
• Cancer care accreditation to incentivize trial enrollment 
• Hire physicians and research staff committed to clinical 
research 
Slow activation of trials due to IRB 
issues, contracting issues, etc. 
• Centralize IRB operations with harmonization across 
countries 
Limited resources at community centers 
to support clinical research 
• Greater partnership between academic and community 
oncology centers 
• Enhanced incentives for patient enrollment in clinical 
trials or referrals to academic centers for clinical trials 
• Education programs for community physicians 
emphasizing the importance of clinical trials 
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Table 2:  Patient Advocacy Groups 
Name of 
Organization 









Provides links to clinical trial 









Clinical trial finder and navigators 
available through TrialConnect 
app.emergingmed.com/abta/home 









Professional staff conduct 
personalized clinical trial searches 
and provide treatment-related 
navigation throughout the 








+44 (0) 1737 813872 
Links to international clinical trial 











Copayment assistance program; 
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Figure 2. Recommended management algorithm for newly-diagnosed primary brain tumor patients 
and potential pitfalls, particularly for under-represented minority populations. 
Abbreviations: GBM (glioblastoma), HGG (high-grade glioma), MRI (magnetic resonance imaging), 
NCCN (National Comprehensive Cancer Network) 
 
 
